Opioid-Induced Bowel Dysfunction
7
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
57%
4 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
The Influence of Tramadol on Opioid-induced Bowel Dysfunction
The Effect of Naldemedine on Opioid-induced Bowel Dysfunction
The Efficacy of Acupressure in Managing Opioid-induced Constipation
Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone